May 14 |
Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)
|
May 7 |
Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference
|
Apr 16 |
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
|
Apr 15 |
Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
|
Apr 15 |
Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies
|
Apr 12 |
Biggest stock movers today: NRIX and APLD
|
Apr 12 |
Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
|
Apr 12 |
Nurix Therapeutics prices upsized stock offering to raise $175 million
|
Apr 12 |
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
|
Apr 11 |
Nurix Therapeutics announces proposed public offering
|